Table 2.
Association between ARBs use and risk of lung cancer
| Models | Binary ARBs exposure | Cumulative Years of Use | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Model1 | 1.06(0.87,1.29) | 0.5713 | 0.95(0.92,0.98) | 0.0046 |
| Model2 | 1.03(0.84,1.25) | 0.7742 | 0.95(0.92,0.98) | 0.0039 |
| Model3 | 1.00(0.82,1.23) | 0.9777 | 0.94(0.91,0.98) | 0.0012 |
| Model4 | 0.95(0.77,1.16) | 0.5907 | 0.93(0.90,0.97) | 0.0002 |
Model 1 estimated crude HR; model 2 was adjusted for age and gender; model 3 was further adjusted for incorporates comorbidities; model 4 was further adjusted for education levels, smoking status, drinking status, COPD exacerbation status, the number of hospital admissions, and comedications